Evaluation of Midkine and Anterior Gradient 2 in a Multimarker Panel for the Detection of Ovarian Cancer

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2010 Jun 8

PMID 20525245

Citations 23

Authors

Gregory E Rice

Tracey A Edgell

Dominic J Autelitano

Affiliations

Soon will be listed here.

Abstract

The aims of this study were: to characterise and compare plasma concentrations of midkine (MDK) in normal healthy women with concentrations observed in women with ovarian cancer; and to establish and compare the performance of MDK with that of anterior gradient 2 protein (AGR2) and CA125 in the development of multi-analyte classification algorithms for ovarian cancer. Median plasma concentrations of immunoreactive MDK, AGR2 and CA125 were significantly greater in the case cohort (909 pg/ml, 765 pg/ml and 502 U/ml, respectively n = 46) than in the control cohort (383 pg/ml, 188 pg/ml and 13 U/ml, respectively n = 61) (p < 0.001). The area under the receiver operator characteristic curve (AUC) for MDK and AGR2 was not significantly different (0.734 +/- 0.046 and 0.784 +/- 0.049, respectively, mean +/- SE) but were both significantly less than the AUC for CA125 (0.934 +/- 0.030, p < 0.003). When subjected to stochastic gradient boosted logistic regression modelling, the AUC of the multi-analyte panel (MDK, AGR2 and CA125, 0.988 +/- 0.010) was significantly greater than that of CA125 alone (0.934 +/- 0.030, p = 0.035). The sensitivity and specificity of the multi-analyte algorithm were 95.2 and 97.7%, respectively. Within the study cohort, CA125 displayed a sensitivity and specificity of 87.0 and 94.6%, respectively. The data obtained in this study confirm that both MDK and AGR2 individually display utility as biomarkers for ovarian cancer and that in a multi-analyte panel significantly improve the diagnostic utility of CA125 in symptomatic women.

Citing Articles

Midkine Serum Levels in Inflammatory and Non-Inflammatory Dilated Cardiomyopathy.

Grabmaier U, Ferraro B, Lehnert K, Petersmann A, Felix S, Weckbach L Biomedicines. 2025; 13(2).

PMID: 40002917 PMC: 11852821. DOI: 10.3390/biomedicines13020504.

Autocrine and paracrine effects of MDK promote lymph node metastasis of cervical squamous cell carcinoma.

Fei H, Chen T, Jiang H iScience. 2024; 27(7):110077.

PMID: 39040052 PMC: 11261016. DOI: 10.1016/j.isci.2024.110077.

From development to cancer - an ever-increasing role of AGR2.

Jach D, Cheng Y, Prica F, Dumartin L, Crnogorac-Jurcevic T Am J Cancer Res. 2021; 11(11):5249-5262.

PMID: 34873459 PMC: 8640830.

Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications.

Kalita-de Croft P, Sharma S, Godbole N, Rice G, Salomon C Cells. 2021; 10(9).

PMID: 34571921 PMC: 8471580. DOI: 10.3390/cells10092272.

The Anterior GRadient (AGR) family proteins in epithelial ovarian cancer.

Fessart D, Robert J, Hartog C, Chevet E, Delom F, Babin G J Exp Clin Cancer Res. 2021; 40(1):271.

PMID: 34452625 PMC: 8394676. DOI: 10.1186/s13046-021-02060-z.

References

Qi M, Ikematsu S, Maeda N, Sakuma S, Noda M, Muramatsu T . Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem. 2001; 276(19):15868-75. DOI: 10.1074/jbc.m005911200. View

Maruyama K, Muramatsu H, Ishiguro N, Muramatsu T . Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2004; 50(5):1420-9. DOI: 10.1002/art.20175. View

Hanley J, McNeil B . A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148(3):839-43. DOI: 10.1148/radiology.148.3.6878708. View

Kadomatsu K . [Midkine, a heparin-binding growth factor: its discovery and functions]. Seikagaku. 1999; 70(11):1315-25. View

Jacobs I, Menon U . Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004; 3(4):355-66. DOI: 10.1074/mcp.R400006-MCP200. View

Edgell T, Martin-Roussety G, Barker G, Autelitano D, Allen D, Grant P . Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol. 2010; 136(7):1079-88. PMC: 2874491. DOI: 10.1007/s00432-009-0755-5. View

Nakanishi T, Kadomatsu K, Okamoto T, Tomoda Y, Muramatsu T . Expression of midkine and pleiotropin in ovarian tumors. Obstet Gynecol. 1997; 90(2):285-90. DOI: 10.1016/S0029-7844(97)00237-8. View

Zou P, Muramatsu H, Sone M, Hayashi H, Nakashima T, Muramatsu T . Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of beta-tectorin gene and in auditory response. Lab Invest. 2006; 86(7):645-53. DOI: 10.1038/labinvest.3700428. View

Maeda N, Kimura T, Kadomatsu K, Muramatsu T, Noda M . A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem. 1999; 274(18):12474-9. DOI: 10.1074/jbc.274.18.12474. View

10.

Ikematsu S, Nakagawara A, Nakamura Y, Ohira M, Shinjo M, Kishida S . Plasma midkine level is a prognostic factor for human neuroblastoma. Cancer Sci. 2008; 99(10):2070-4. PMC: 11159802. DOI: 10.1111/j.1349-7006.2008.00957.x. View

11.

Liu D, Rudland P, Sibson D, Platt-Higgins A, Barraclough R . Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res. 2005; 65(9):3796-805. DOI: 10.1158/0008-5472.CAN-04-3823. View

12.

Pepe M, Etzioni R, Feng Z, Potter J, Thompson M, Thornquist M . Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93(14):1054-61. DOI: 10.1093/jnci/93.14.1054. View

13.

Fletcher G, Patel S, Tyson K, Adam P, Schenker M, Loader J . hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer. 2003; 88(4):579-85. PMC: 2377166. DOI: 10.1038/sj.bjc.6600740. View

14.

Yuki T, Ishihara S, Rumi M, Ortega-Cava C, Kadowaki Y, Kazumori H . Increased expression of midkine in the rat colon during healing of experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2006; 291(4):G735-43. DOI: 10.1152/ajpgi.00388.2005. View

15.

Gorelik E, Landsittel D, Marrangoni A, Modugno F, Velikokhatnaya L, Winans M . Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(4):981-7. DOI: 10.1158/1055-9965.EPI-04-0404. View

16.

Garver Jr R, Radford D, Donis-Keller H, Wick M, Milner P . Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer. 1994; 74(5):1584-90. DOI: 10.1002/1097-0142(19940901)74:5<1584::aid-cncr2820740514>3.0.co;2-v. View

17.

Abe Y, Tsutsui T, Mu J, Kosugi A, Yagita H, Sobue K . A defect in cell-to-cell adhesion via integrin-fibronectin interactions in a highly metastatic tumor cell line. Jpn J Cancer Res. 1997; 88(1):64-71. PMC: 5921243. DOI: 10.1111/j.1349-7006.1997.tb00303.x. View

18.

Tomomura M, Kadomatsu K, Nakamoto M, Muramatsu H, Kondoh H, Imagawa K . A retinoic acid responsive gene, MK, produces a secreted protein with heparin binding activity. Biochem Biophys Res Commun. 1990; 171(2):603-9. DOI: 10.1016/0006-291x(90)91189-y. View

19.

Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T . Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem. 1999; 73(5):2084-92. View

20.

Tao P, Xu D, Lin S, Ouyang G, Chang Y, Chen Q . Abnormal expression, highly efficient detection and novel truncations of midkine in human tumors, cancers and cell lines. Cancer Lett. 2007; 253(1):60-7. DOI: 10.1016/j.canlet.2007.01.019. View